home / stock / avdl / avdl news

AVDL News and Press, Avadel Pharmaceuticals plc From 05/14/21

Stock Information
Company Name: Avadel Pharmaceuticals plc
Stock Symbol: AVDL
Market: NASDAQ
Website: avadel.com
Menu
AVDL AVDL Quote AVDL Short AVDL News AVDL Articles AVDL Message Board
Get AVDL Alerts

News, Short Squeeze, Breakout and More Instantly...
AVDL - Avadel to 'vigorously' defend against patent violations claims filed by Jazz

Yesterday, Jazz Pharmaceuticals (JAZZ) filed a complaint in Delaware federal court against Avadel Pharmaceuticals (AVDL) regarding an alleged infringement of five patents linked to the company’s blockbuster therapy Xyrem.The FDA application sought by Avadel to market its narcolepsy dru...
AVDL - Avadel Pharmaceuticals plc (AVDL) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q1 2021 Earnings Call May 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q1 2021 Earnings Call Transcri...

AVDL - Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2021 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc (AVDL) Q1 2021 Earnings Conference Call May 10, 2021 8:30 A.M. ET Company Participants Tom McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Richard Kim - Chief Commercial Officer ...

AVDL - Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA date Presented positive secondary endpoint data at the AAN 2021 Annual Meeting, which further highlights the overall clinical value proposition of FT218 FT218 launch prepar...
AVDL - Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, anno...

AVDL - Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting

Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company foc...

AVDL - Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021

DUBLIN, Ireland, April 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today annou...
AVDL - Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel's Third Annual CNS Day on March 31st

DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced t...

AVDL - Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Call Transcript

Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q4 2020 Earnings Call Mar 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Call Transcrip...

AVDL - Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript

Start Time: 08:30 End Time: 09:25 Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Conference Call March 09, 2021, 08:30 AM ET Company Participants Greg Divis - CEO Thomas McHugh - CFO Richard Kim - Chief Commercial Officer Jennifer Gudeman - VP of Medical and Clinical Affairs Conference Ca...
Previous 10 Next 10